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ABSTRACT
Coronavirus disease 2019 (COVID-19) is a worldwide outbreak caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World 
Health Organization (WHO) has declared it as a public health emergency of 
international concern (PHEIC) and eventually a pandemic. Many clinical 
trials have been conducted to investigate potential and effective therapies 
for COVID-19. Here we reported the outcome of three COVID-19 cases treated 
early with the combination of hydroxychloroquine and azithromycin. Early 
treatments of suspected or confirmed positive COVID-19 cases with this 
combination therapy is to avoid disease progressions into a more severe and 
irreversible state. In these cases, clinical, radiological, and laboratory features 
were followed up. No complications were observed. The COVID-19 patients 
treated with this early combination therapy showed good responses.
ABSTRAK
Coronavirus diseases 2019 (COVID-19) adalah penyakit yang telah menjadi 
wabah di seluruh dunia dan disebabkan oleh Severe Acute Respiratory 
Syndrome Coronavirus 2 (SARS-CoV-2). Organisasi Kesehatan Dunia (WHO) 
telah menetapkan kondisi ini dalam kategori public health emergency 
of international concern (PHEIC) dan juga menetapkan sebagai sebuah 
pandemi. Banyak uji klinis dilakukan untuk menemukan terapi potensial dan 
efektif untuk COVID-19. Kami melaporkan luaran dari tiga seri kasus yang 
mendapatkan pengobatan awal dengan kombinasi hidroksikloroquin dan 
azitromisin. Tujuan  pengobatan terhadap pasien tersangka maupun yang 
telah terkonfirmasi positif COVID-19 dengan menggunakan terapi kombinasi 
obat ini pada tahap awal penyakit adalah untuk mengurangi progresivitas 
penyakit menjadi lebih parah dan ireversibel. Pemeriksaan klinis, radiologi, 
dan hasil laboratorium diikuti untuk melihat kondisi pasien. Tidak ada 
komplikasi yang ditemukan. Pasien yang diobati dengan terapi kombinasi ini 
menunjukkan respon yang baik. 
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) 
is a global outbreak caused by severe 
acute respiratory syndrome coronavirus 
2 (SARS-CoV-2).  It was first reported 
in Wuhan, China on December 2019, 
before rapidly spreading to the rest 
of the world.1-3 As of May 29, 2020, 
there have been more than 5.7 million 
cases and 350,000 deaths in more 
than 200 countries.4 The World Health 
Organization (WHO) has declared this 
situation as a public health emergency 
of international concern (PHEIC) and 
eventually a pandemic.  Current pieces 
of evidence suggest that SARS-CoV-2 
can be transmitted via droplets, close 
contacts, and contaminated objects. 
The incubation period ranges from 2-14 
days.5,6
The classic symptoms of COVID-19 
include fever, dry cough, shortness 
of breath, sore throat, malaise, and 
diarrhea. Anosmia and ageusia can be 
found in some cases. Acute respiratory 
distress syndrome and septic shock have 
occurred in severe cases. Chest imaging 
has shown multiple infiltrative patches 
and ground glass appearance in both 
lungs.6,7
There is an urgent need to treat the 
disease and to limit the duration of virus 
carriage with an effective treatment. 
Among drug candidates to treat 
COVID-19, hydroxychloroquine (HCQ) 
and azithromycin (AZ) are suggested to 
have beneficial effects when they are 
simultaneously administered. Since both 
drugs have been shown to have antiviral 
activities, such combination may both 
act as an antiviral therapy and prevent 
bacterial super-infections.8-11 Therefore, 
these two drugs are administered for 
suspected or COVID-19 positive patients. 
However, both drugs still have limited 
clinical evidence on its efficacy for 
COVID-19.12 In this report, we present 
three cases of COVID-19 patients 
receiving early combined therapy with 
HCQ and AZ. “Early state” is defined 
as highly suspected COVID-19 patients, 
but quantitative reverse transcription-
polymerase chain reaction (RT-PCR) 
results from nasopharyngeal swab have 
not been obtained.13 Signed informed 
consent was received from each patient 
presented in this case series. All three 
patients were treated in the Academic 
Hospital of Universitas Gadjah Mada, 
a referral hospital in Yogyakarta, 
Indonesia.
CASE 1
A 70-year-old woman was referred 
to the emergency unit with a chief 
complaint of fever for two weeks. The 
patient also felt nauseous, shortness of 
breath, fatigue, and sometimes cough. 
The patient has a previous medical 
history of hypertension. The patient had 
a travel history to Semarang, Central 
Java (a local transmission region in 
Indonesia) two weeks before hospital 
admission. 
Vital sign examinations on admission 
were: blood pressure 130/80 mmHg, 
heart rate 76 bpm, respiratory rate 36x/
min, temperature 36.9oC, SpO2 90% room 
air, and 97% with 4 Liters per minute 
(lpm) oxygen via nasal cannula. No 
murmur or gallops were found during 
heart auscultations. Lung auscultation 
found crackles on both lungs.
Laboratory results were white blood 
cell (WBC) count 5500/uL, neutrophil 
69.1%, lymphocyte 26.1%, monocyte 
3.9%, hematocrit (HCT) 37%, hemoglobin 
(HB) 12.6 g/dL, platelet (PLT) 227.000/uL, 
potassium 3.1 mmol/L, ureum 15.5 mg/
dL, creatinine 0.65 mg/dL, procalcitonin 
0.09 ng/ml, positive C-reactive protein 
(CRP) 24 ug/ml, and postprandial blood 
glucose 206 mg/dL. No bacteria were 
detected in the sputum culture.The 
electrocardiogram (ECG) showed normal 
sinus rhythm and had a QTc interval of 
less than 500 ms (475 ms). Chest X-ray 
revealed infiltrate in the right suprahilar 
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region (FIGURE 1). 
We performed reverse transcription-
polymerase chain reaction (RT-PCR) for 
COVID-19 testing by the nasopharyngeal 
swab. However, the result was 
delayed due to overload samples in the 
reference laboratory in our provincial 
regions. At the beginning of the 
pandemic, there was only one reference 
laboratory in our province that was 
able to perform RT-PCR for COVID-19. 
Thus, the patient was diagnosed with 
suspected severe COVID-19, mild 
hypokalemia, hyperglycemia, and 
primary hypertension. She was treated 
with hydroxychloroquine 400 mg per 
orally (PO) BID on the first day and 
continued with 200 mg BID until 5 days. 
We combined it with azithromycin 500 
mg PO QD for 5 days. We also treated 
her comorbid conditions (candesartan 
8 mg PO QD, metformin 500 mg PO QD, 
paracetamol 500 mg PO TID, KSR 1 tablet 
PO QD, and curcuma 1 tablet PO TID).
Oxygen requirement was increased 
from 4 lpm oxygen via nasal cannula on 
arrival to 8 lpm with a non-rebreathing 
mask on day 2 (oxygen saturation was 95-
97%). On day 3, it was given back to 4 lpm 
oxygen via nasal cannula. Improvement 
was observed on day 5 without oxygen 
via nasal cannula (oxygen saturation 
96%). An ECG follow-up showed normal 
results (QTc interval 428-435 ms).
RT-PCR had not existed yet on day 
6 since hospitalization, but the clinical 
condition was stable. We decided to 
discharge the patient by educating 
the COVID-19 protocol to prevent 
transmission, and we evaluated one 
week later after the discharge. Then, 
the first and second RT-PCR results were 
positive.
During clinical evaluation at one 
week after the discharge, the patient 
was free from any signs and symptoms. 
Complete blood count was within normal 
limit, postprandial blood glucose was 
134 mg/dL, negative CRP, and chest X-ray 
was normal (FIGURE 1). The patient was 
treated for her previously established 
diseases (metformin 500 mg PO QD 
and amlodipine 10mg PO QD), and the 
multivitamin was given. The RT-PCR 
from nasopharyngeal swabs were still 
positive on day 21st and 22nd. Evaluation 
RT-PCR from nasopharyngeal swabs 
on day 28th and 29th after onset were 
negative. Thus, the patient had a full 
recovery. 
CASE 2
A 42-year-old man was admitted 
to the hospital with a chief complaint 
of shortness of breath since three days 
prior to admission,followed by cough, 
fever, and hypogeusia. The patient had 
a contact history with COVID-19 patient 
several days before admission. Vital signs 
on presentation included blood pressure 
118/78 mmHg, heart rate 110 bpm, 
respiratory rate 22x/min, temperature 
37.9oC, SpO2 97% with 3 lpmoxygen via 
nasal cannula. No murmur or gallops 
were found, and lung auscultation found 
crackles on both lungs. 
The laboratory results were WBC 
count 5800/uL, neutrophil 69.2%, 
lymphocyte 20.3%, monocyte 10.3%, 
HCT 40.1%, HB 13.6 g/dL, PLT 180000/
uL, potassium 3.8 mmol/L, sodium 135 
mmol/L, chloride 95 mmol/L, ureum 16 
mg/dL, creatinine 0.74mg/dL, positive 
CRP, serum glutamic oxaloacetic 
transaminase(SGOT) 45 u/L, serum 
glutamic pyruvic transaminase (SGPT) 
40 u/L, and blood gas analysis were pH 
7.45, PCO2 29.0 mmHg, cHCO3 19 mmol/l, 
and PO2 98.7 mmHg.
The ECG result was normal sinus 
rhythm and had a QTc interval of less 
than 500 ms (344 ms). The chest X-ray 
revealed bilateral pneumonia (FIGURE 
1). The first RT-PCR from nasopharyngeal 
swab was positive for SARS-CoV-2. 
Thus, the patient was diagnosed with 
moderate COVID-19. He was treated 
with hydroxychloroquine 400 mg PO 
BID on the first day and continued with 
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200 mg BID for 10 days combined with 
azithromycin 500 mg PO QD on the first 
day and continued with 250 mg QD for 
4 days. Paracetamol 500 mg PO TID, 
multivitamin (caviplex) one tablet PO 
BID, N-acetylcysteine (NAC) 200 mg PO 
TID, and vitamin C injection 200mg TID 
were given as supportive treatment. 
There were no fever and shortness of 
breath, only cough remained on day 3.
The second RT-PCR from 
nasopharyngeal swab was still positive 
on day 4. No symptoms were reported 
but the CRP test was still positive on day 
5. Follow-up ECG showed normal results 
(QTc interval 409-423 ms). The chest 
X-ray showed improvement and RT-PCR 
nasopharyngeal swabs were negative on 
day 11 and 12, consecutively. The chest 
X-ray showed further improvement 
on day 18 (FIGURE 1). The patient was 
discharged on the 19th day.
CASE 3
A30-year-old woman was admitted 
to the hospital with a chief complaint 
of fever for 3 days. The patient also 
complained of cough and sore throat. 
She had close contact with her husband 
who died of COVID-19. Vital signs on 
presentation included: blood pressure 
110/70 mmHg, heart rate 110 bpm, 
respiratory rate 20x/min, temperature 
37.8oC, SpO2 98% at room air. Heart 
and lung examinations were within 
normal limits. The laboratory results 
were WBC count 4300 u/L, neutrophil 
49.1%, lymphocyte 42.1%, monocyte 
8.6%, HCT 43.8%, HB 15.0 g/dL, PLT 
111000 u/L, positive CRP, and negative 
immunoglobulin (Ig) G and M (IgG/IgM)of 
SARS-CoV-2 antibody test. ECG revealed 
sinus tachycardia (heart rate 122 bpm)
and had a QTc interval of less than 500 
ms (390 ms). The patient was diagnosed 
with acute upper respiratory infection 
and acute pharyngitis. Mild infection 
of SARS-CoV-2 was suspected. Since the 
clinical diagnosis of this patient was 
acute upper respiratory infection, we did 
not perform chest X-ray examination.
She was treated with 
hydroxychloroquine 400 mg PO BID on 
the first day and continued with200 mg 
PO BID for seven days. We also treated 
her with azithromycin 500 mg PO QD 
for 6 days. Paracetamol 500 mg PO TID, 
multivitamin (caviplex) 1 tablet PO BID, 
curcuma 1 tablet PO TID, N-acetylcysteine 
(NAC) 200 mg PO BID, and vitamin C 
injection 200 mg TID as supportive 
treatment. We did an RT-PCR test for 
SARS-CoV-2 from nasopharyngeal swab 
on day 2 and day 3 and the results were 
positive. The diagnosis of mild COVID-19 
was established. CRP test was negative on 
day 6. There were no symptoms since day 
3 but ECG still showed sinus tachycardia 
and had QTc interval 370-419 ms until 
day 7. The ECG was normal on day 8. We 
conducted IgG/IgM SARS-CoV-2 antibody 
test on day 9 and the result was positive. 
RT-PCR from nasopharyngeal swab was 
delivered on day 13 and day 14, and the 
results were negative. The patient was 
later discharged after 17 days of hospital 
admission.
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CXR on admission CXR on discharged
FIGURE 1. Chest X-ray examination for patient 1 (A and B) and patient 2 (C and D), 
both on admission (A and C) and discharge (B and D).
The clinical course of all cases are summarized in TABLE 1.













1 Day 1 Day 1 Day 10 Day 5 Day 20
2 Day 1 Day 1 Day 6 Day 3 Day 8
3 Day 1 Day 1 Day 11 Day 3 Day 12
  A
    B
  C    D
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DISCUSSION
The therapeutic management 
of patients is an urgent need to 
treat symptoms, shortening viral 
shedding, and avoiding progression 
to a serious state. By administering 
hydroxychloroquine in combination 
with azithromycin in early state, we 
were able to observe improvement in 
all three cases. It is necessary to avoid 
a worsening progression, which usually 
occurs around the tenth day and may 
result in acute respiratory distress 
syndrome, the prognosis of which, in 
particular in the elderly, is poor.12
The protocol in our hospital is 
patient with highly suspected COVID-19 
should get additional examination 
(complete blood count, chest X-ray, 
ECG, RT-PCR on day 1 and day 2, and 
other examinations based on clinical 
indications). RT-PCR is only performed 
to person under surveillance who 
has positive rapid diagnostic test or 
patient under observation. If there is 
no contraindication, the patient will 
be given hydroxychloroquine and 
azithromycin in the early state. Vitamin C 
and symptomatic treatment can be given 
as supportive treatment. This protocol 
is in accordance with the guideline of 
COVID-19 treatment in Indonesia.13 Then, 
the patient should be followed up for 
clinical signs and symptoms, ECG, and 
chest X-ray (if there is pneumonia). If the 
results of RT-PCR were positive, the third 
and fourth RT-PCR should be performed. 
The patient can be discharged if the 
third and fourth results of RT-PCR were 
negative. The additional examination 
should be performed based on the 
indication of evaluation. If the results 
were still positive, fifth and sixth RT-
PCR should be performed. The RT-PCR is 
continually repeated until there are two 
consecutive negative results.
Severity of the disease is 
associated with high viral RNA load in 
COVID-19 patients. In these cases, the 
combination of hydroxychloroquine and 
azithromycin is found to be effective in 
clearing viral nasopharyngeal carriage 
of SARS-CoV-2 in COVID-19 patients 
within only three to six days.8 We might 
have seen better results than three to 
six days. However, due to the sampling 
protocol in our hospital, we could only 
obtain specimen for re-examination 
when there is resolution of clinical signs 
and symptoms. These results appear to 
be superior because a recent study from 
China has shown that the mean duration 
of viral shedding in COVID-19 patients 
without specific treatment was 20 days 
(even 37 days for the longest duration).14,15 
The rapid decrease in viral load is a 
synergistic effect of the combination 
between hydroxychloroquine and 
azithromycin. The combination of these 
drugs has a positive role to limit the 
duration of viral shedding that later can 
slow down the epidemic.16
We observed prolonged positivity 
(more than 20 days since hospital 
admission) of RT-PCR results in Case 
1. A previous study showed that this 
observation was more commonly 
found in patients aged ≥65 years old, 
similar to our present case.17 This study 
also showed that 26.3% of samples 
remained positive for SARS-CoV-2 after 
4 weeks (>28 days), suggesting prolonged 
viral replications in those groups of 
patients.17 Interestingly, another study 
reported that viral infectivity (defined 
by observed viral growth in cell culture) 
was low when positive RT-PCR results 
were obtained more than 8 days after 
symptom onset.18 This study suggests that 
prolonged positive RNA detections may 
represent the presence of non-viable 
virus, although we could not confirm 
in our patients due to lack of viral cell 
culture facilities.
Hydroxychloroquine is a relatively 
safe drug with a promising profile 
against SARS-CoV-2. However, 
hydroxychloroquine  also has  toxic  effects. 
The incidence of hydroxychloroquine 
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overdose is low. It can be occurred 
when dosing at 20 mg/kg and has been 
fatal at over 30 mg/kg. The effects of 
overdose are nausea, drowsiness, visual 
disturbance, hypokalemia, convulsion, 
shock, and death.19The combination of 
hydroxychloroquine and azithromycin 
has a potential risk to induce severe 
QT prolongation. Therefore, we need 
to consider to perform ECG before 
starting the treatment. Hospitalizing 
patients with ECG monitoring can 
help in preventing cardiac side effects 
through early detection. In a few studies, 
there is possible toxicity from this drug 
combination.20,21 However, in our case 
series, there was no observed toxicity. 
Further studies of this treatment 
should be conducted to evaluate its 
double effects as antibacterial and 
antiviral therapy for COVID-19. These 
effects can eliminate the infection, hence 
reduce viral transmission in order to 
curb the spread of this pandemic. The 
possibility of this treatment being an 
international strategy to fight COVID-19 
should be considered.
CONCLUSION
Since the emergence of the COVID-19 
pandemic, there is an urgent need to 
effectively treat the disease and limit the 
duration of virus carriage. Many clinical 
trials have been conducted to investigate 
the potential therapies for COVID-19. 
We have shown that early combination 
therapy with hydroxychloroquine 
and azithromycin shows good clinical 
and virological (clearance) responses 
in our COVID-19 patients with no 
observable side effects. Therefore, 
further comprehensive studies are 
highly required to explore the role of this 
treatment for COVID-19.
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